

Effects of adjuvants on IgG subclasses elicited by virus-like Particles

Visciano *et al.*

RESEARCH

Open Access

Effects of adjuvants on IgG subclasses elicited by virus-like Particles

Maria Luisa Visciano, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro and Luigi Buonaguro*

Abstract

Background: Virus-Like Particles (VLPs) represent an efficient strategy to present and deliver conformational antigens to the immune system, inducing both arms of the adaptive immune response. Moreover, their particulate structure surrounded by cell membrane provides an adjuvanted effect to VLP-based immunizations. In the present study, the elicitation of different patterns of IgG subclasses by VLPs, administered in CpG ODN1826 or poly(I:C) adjuvants, has been evaluated in an animal model.

Results: Adjuvanted VLPs elicited a higher titer of total specific IgG compared to VLPs alone. Furthermore, while VLPs alone induced a balanced T_H2 pattern, VLPs formulated with either adjuvant elicited a T_H1 -biased IgG subclasses (IgG2a and IgG3), with poly(I:C) more potent than CpG ODN1826.

Conclusions: The results confirmed that adjuvants efficiently improve antigen immunogenicity and represent a suitable strategy to skew the adaptive immune response toward the differentiation of the desired T helper subset, also using VLPs as antigen.

Introduction

The development of a safe and effective HIV-1 vaccine, either prophylactic or therapeutic, remains a major concern and a high priority for the scientific community. In this respect, given that strategies based on attenuated or inactivated pathogens are not suitable as HIV vaccines for safety reasons, alternative effective vaccination strategies are developed and evaluated [1].

In this framework, Virus-Like Particles represent a highly attractive type of subunit vaccine since they are self-assembling, non-replicating, non-pathogenic particles, similar in size and conformation to intact virions [2]. Moreover, VLPs can enter both MHC class I and class II antigen processing pathways in antigen presenting cells [3,4], eliciting both humoral and cellular immune responses [5]. VLP vaccines have been developed and licensed for HBV as well as HPV and immunological studies have showed induction of protective humoral and cellular immunity [6-8]. Additional VLP based vaccine for other viruses such as HCV, influenza virus and HIV-1 are in different stages of pre-clinical and clinical trial [9-15].

Human IgG consists of four subclasses contributing in different ways to humoral immunity against pathogens. Individual subclasses are elicited by different type of antigens: antibody responses to viral and bacterial protein antigens are mainly restricted to IgG1 and IgG3 [16-19], while IgG2 is generally produced in response to carbohydrate antigens [20-22]. In this regards, subjects with decreased levels of IgG2 antibodies show poor antibody responses to polysaccharide vaccines [23], suggesting this subclass is responsible for protection against encapsulated pathogens. In addition, several factors, including the structure and quantity of antigen [24] as well as the route and duration of antigenic stimulation may affect the subclass of IgG antibody produced. In particular, IgG1 and IgG3 subclasses mediate important protective, biological functions such as complement fixation, opsonization and induction of ADCC by NK cells [25,26].

Mice, similarly to humans, show four different classes of IgGs, named IgG1, IgG2a, IgG2b and IgG3, which functionally correspond to the human IgG1, IgG2, IgG4 and IgG3, respectively. Nevertheless, differences can be observed among the two animal species in the IgG subclasses to bind FcR, to fix complement or to undergo to cytokine-induced subclass switching [27]. Despite these

* Correspondence: ircsvir@unina.it
Lab. of Molecular Biology and Viral Oncogenesis, Istituto Nazionale Tumori "Fond. G. Pascale", Naples-Italy

differences, the overall structure of the humoral IgG pattern in mice and humans can be considered quite similar. In general, it is possible to conclude that in mice and humans IgG1 (as well as IgG4 in humans) is associated with a T_H2 profile and the other subclasses are mainly associated with a T_H1 profile [28].

As for other infectious diseases, the pattern of IgG subclass has been shown to play a role in the course of HIV infection and it has been reported to vary with progression status. Subjects enrolled in the French Asymptomatic Long-Term (ALT) cohort showed a strong IgG1 responses to Env and Pol antigens as well as a broad IgG subclass response to p24 [29]. Further studies have shown that anti-HIV humoral response characterized by a broad spectrum of IgG subclasses is associated with a non-progressor status [28,30].

Such observation strongly suggest that, in order to be protective, a HIV vaccine should elicit a broad and balanced IgG subclass immune response. So far all the soluble gp120 glycoprotein based HIV-1 vaccines have shown to elicit mainly IgG1 subclass antibodies both in humans and mouse, indicating a T_H2 skewed response [31-34], and strategies to switch to a broader IgG subclass profile have been proposed [32,34]. Alternative vaccine approaches have been shown to induce a more balanced T_H1 and T_H2 response [35] or a T_H1 skewed response [36,37]. In particular, adjuvants used in the vaccine formulation may influence the IgG profile, with CpG and MPL inducing a T_H1 skewed immune response [38-42] while Al(OH)₃ a T_H2 profile [43,44].

Virus-like particles (VLPs) developed in our laboratory are based on the HIV-1 Pr55gag precursor protein (HIV-VLPs) and display a trimeric gp140 molecule from an Ugandan HIV-1 isolate of the A clade [45-48]. Such HIV-VLPs have shown to induce HIV-1-specific CD4+ and CD8+T cell responses as well as cross-clade neutralizing antibodies in immunized Balb/c mice [49,50]. Moreover, the intraperitoneal and intranasal administration of HIV-VLPs in mice have demonstrated to induce antibody responses at systemic as well as mucosal (vaginal and intestinal) levels [13,14]. Furthermore, we have previously reported that baculovirus-expressed HIV-1 VLPs developed in our laboratory induce secretion of both T_H1 and T_H2 cytokines in Monocyte-Derived Dendritic Cells (MDDC) [51,52] as well as in PBMCs [53,54].

In order to evaluate whether the pattern of IgG subclasses induced by baculovirus-expressed HIV-VLPs could be broaden and/or skewed toward a more pronounced T_H1 profile, immunogenicity studies were performed using the two T_H1-skewing adjuvants, CpG ODN1826 and poly(I:C) [55-57]. In particular, poly(I:C) is a synthetic double stranded RNA that potently induces IL-12 and type I IFNs through activation of innate

immunity via endosomally expressed TLR3 and the cytoplasmic receptor MDA-5 [58,59]. Induction of type I IFNs results into DC maturation and B cell activation, followed by initiation of potent CD4+T cell and humoral immune responses, as shown in mice [60,61] and in non-human primates [42,62]. Furthermore, type I IFNs have been shown to induce, in a mouse model, cross presentation of proteins to generate CD8+ T cell responses [63,64].

CpG ODNs are synthetic oligonucleotides containing unmethylated CpG dinucleotides with specific motifs recognized by the innate immune system of vertebrates [65]. These motifs represent the ligand for TLR-9 expressed intracellularly in phagocytic cells [66] and can induce maturation, differentiation and proliferation of different immune cell types [67-71]. Upon induction, immune cells secrete cytokines and chemokines that create a T_H1 biased immune environment [72-75]. Vaccines formulated with CpG motifs have been shown to elicit both cellular and humoral response [76-78].

The results in the present study show that both adjuvants, and more potently poly(I:C), are able to skew the immune response to HIV-VLPs toward a T_H1 profile.

Material and methods

VLPs preparation

HIV-1 Virus-like Particles expressing on their surface modified HIV gp140 Clade A were prepared as previously described [79]. Briefly, HighFive insect cells, derived from *Trichoplusia ni* egg cell homogenates (Invitrogen Inc.), were propagated in SF900 serum-free medium supplemented with 1% antibiotics (Gibco-BRL) and 9×10^5 cells seeded in a 6-well plate were transfected with 10-20 μ g of recombinant bacmid DNA, by the Cellfectin method (Gibco-BRL). After 72 hr incubation, recombinant baculovirus released in the supernatant of transfected cells (Passage 1) was used to infect 2×10^6 HighFive cells/well and the released recombinant baculovirus was collected after 72 hr incubation (Passage 2). A further infection step was performed to obtain the Passage 3 recombinant baculovirus to be used for large-scale VLPs preparation. HighFive cells were propagated in suspension and 4×10^9 cells were infected with the P3 recombinant baculovirus at a multiplicity of infection (M.O.I.) of 5 in a final volume of 100 ml. After 5 hr incubation in orbital shaker, cells were diluted with SF900 culture medium to a concentration of 1×10^6 /ml and incubated for 96 hrs in orbital shaker. Subsequently, supernatants were clarified by centrifugation at 2,000 g for 15 min at 4°C and VLPs were pelleted by ultra-centrifugation at 100,000 g for 75 min through a 25% sucrose cushion, as previously described [47,80] and resuspended in TNE buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl and 1 mM EDTA).

Immunization study

For the immunization study, 6 female Balb/c mice of 6-8 weeks old were immunized subcutaneously with 20 µg of HIV-VLP in combination or not with 20 µg of CpG ODN1826 or 100 µg of poly(I:C) (both from InvivoGen) as adjuvants. Mice received a priming and two homologous boosts, three weeks apart from each other. Blood samples were collected with retro-orbital puncture a week after each injection; sera were heat inactivated and stored at -80°C until used. Animal experiments were carried out following internationally recognized guidelines and were approved by the Italian Ministry of Health.

ELISA

All ELISA determinations individually described below were developed with the following procedure. Positive reactions were visualized with TMB Ultra 1-step solution (Thermo Scientific) and stopped with 2N sulfuric acid. Absorbance was determined at O.D.450 nm and reactions were considered positive when exceeding the mean absorbance +3 standard deviations of equal dilutions of pre-immunization sera collected from animals. The antibody (Ab) levels were evaluated as the geometric mean titer of the last positive dilution of sera from the animals of each set. In all ELISA pre-immunization sera have been used as negative control.

Measurement of specific anti-HIV IgG antibodies in mouse serum

The level of IgG antibodies in sera of immunized mice was determined by ELISA. Briefly 96-well MICROTTEST assay plates (Becton Dickinson) were coated with 100 ng/well of B clade p24 (NIBSC-CFAR, Catalog #EVA620) or homologous A clade trimeric gp140 and incubated overnight at 4°C. Three-fold dilutions of mouse sera starting at a 1:100 dilution, were added to each well and incubated 2 hrs at 37°C. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Thermo Scientific) was added to each well at a concentration of 1 µg/mL (100 ng) and incubated 2 hrs at 37°C.

Determination of anti-gp140 and anti-p24 specific IgG subclasses

Specific anti-gp140 and anti-p24 IgG subclasses were determined by ELISA in sera of mice immunized as previously described. Specific HRP-conjugated goat anti-mouse IgG₁ or biotin-conjugated goat anti-mouse IgG_{2a}, IgG_{2b} and IgG₃ (all from Southern Biotech) were added individually to each well and incubated for 2 hr at 37°C. The anti mouse IgG₁ was used at a 1:2,000 dilution. Alternatively, the biotin-conjugated goat anti-mouse IgG_{2a}, IgG_{2b} and IgG₃ were used at a 1:5,000 dilution and a third HRP-conjugated anti-biotin Ab (Cell

Signaling) was added to each well at 1:1,000 dilution for an additional 1 hr incubation at 37°C.

Overtime evaluation of anti-gp140 and anti-p24 specific humoral immune response

The trend of the humoral immune response during the immunization protocol was evaluated. At each time point, three-fold dilutions of pooled sera from immunization groups were added to each well coated with recombinant gp140 or p24. Specific anti-mouse HRP-conjugated IgG was then added at 1 µg/mL concentration and plates were incubated for 2 hours at 37°C.

T_H1: T_H2 index calculation

To determine whether the addition of adjuvants in the immunization protocol induced a T_H1 (IgG2a and IgG3) or T_H2 (IgG1) polarization, we proceeded as follows. The reciprocal value of the titer at last positive dilution for each IgG subclass was considered for each immunization protocol. The T_H1:T_H2 index was then calculated as $([IgG2a+IgG3]/2)/(IgG1)$. According to such calculation, an index value < 1 stands for a T_H2 polarization; an index value > 1 stands for a T_H1 polarization.

Statistical analysis

Intergroup comparisons were performed with the unpaired two-sided Student's t-test. All P values were two-tailed and considered significant if less than 0.05.


Results

Immunization with HIV-1 VLP induces specific antibodies to HIV-1 antigens

In order to determine the effect of CpG ODN1826 and poly(I:C) adjuvants on the humoral response elicited by baculovirus-expressed HIV-VLPs developed in our laboratory, Balb/c mice were immunized by intradermal route with 20 µg of VLPs alone or formulated with the two adjuvants. Sera collected after the last boosting from all immunization groups were heat-inactivated and evaluated in ELISA against HIV-1 p24 and trimeric gp140. The results showed that both adjuvants were able to enhance the immunogenicity of HIV-VLPs eliciting a final 1:8,100 (CpG ODN1826) and 1:24,300 (poly(I:C)) titer of IgG to both p24 and gp140 (Figure 1). Such results confirm data recently reported by our Group, showing the enhanced immunogenicity of VLPs when formulated in CpG ODN1826 [81].


Kinetic of anti HIV-1 humoral immune response

In order to determine how the anti-p24 and anti-gp140 immune responses develop in the course of the immunization protocol, sera were reacted in ELISA with recombinant gp140 or p24 after each antigen administration.



In particular, sera from each group of immunized animals were pooled.

The results for both p24 and gp140 showed that the trend of total IgG titers is quite similar for sera from each immunization group, although those from animals immunized with poly(I:C)-adjuvanted HIV-VLPs showed a more sustained fashion (Figure 2A and 2B). Concerning




the p24, the formulation of VLPs in either CpG ODN1826 or poly(I:C) induced an enhancement of total IgG titers after the third administration, compared to HIV-VLPs alone (Figure 2B). In particular, the CpG ODN1826 induced a 3-fold enhancement (1:8,100 vs 1:2,700) and the poly(I:C) induced a 9-fold enhancement (1:24,300 vs 1:2,700) ($p < 0.05$). Similar enhancement in the total IgG titers were observed for the gp140 (Figure 2A).


T_H1 polarization induced by HIV-VLPs formulated in adjuvants

The pattern of IgG subclasses induced by the different immunization protocols was evaluated by using secondary goat anti-mouse antibodies specific for each IgG subclass.

Sera from animals immunized with HIV-VLPs alone showed anti-p24 low titers (1:300) of both T_H2 IgG1 and T_H1 IgG3 subclasses, while no IgG2a or IgG2b were detected (Figure 3). The formulation of HIV-VLPs in CpG ODN1826 adjuvant did not enhance IgG1 and IgG3 titers, but induced a 9-fold enhancement in anti-p24 IgG2a and IgG2b titers (1:900) compare to HIV-VLPs alone (Figure 3). In contrast, HIV-VLPs formulated in poly(I:C) adjuvant induced significantly higher titers of all four IgG subclasses (Figure 3), with the highest titers observed for T_H1 subclasses (IgG2a = IgG2b > IgG3 > IgG1).

Similar results were observed for anti-gp140 response (Figure 4). Sera from animals immunized with HIV-VLPs alone showed medium/low titers of both T_H2





IgG1 and T_H1 IgG3 subclasses, while no IgG2a were detected. However, in contrast to results for anti-p24, low titers of IgG2b anti-gp140 were detected (Figure 4). The formulation of HIV-VLPs in CpG ODN1826 adjuvant induced a 3-to-9-fold enhancement in the IgG2a and IgG2b titers (1:900) compared to HIV-VLPs alone. No enhancement effects on IgG1 and IgG3 titers were observed. In contrast to results on p24, HIV-VLPs formulated in poly(I:C) adjuvant induced significantly higher titers of only T_H1 IgG subclasses, with no enhancement of IgG1 titers (IgG2a = IgG2b > IgG3 > IgG1) (Figure 4). The analysis of titers was supported by statistical significance ($p < 0.05$).

Such results indicate that antibody profile induced by HIV-VLPs in mice is T_H2 for both p24 and gp140 and that formulation in either CpG ODN1826 or poly(I:C) adjuvant results in a T_H1 skewed IgG pattern.

T_H1 : T_H2 index calculation

To assess whether the adjuvant formulation elicited a specific IgG subclass profile or induced an increment in all subclasses, a T_H1 : T_H2 index was calculated for each immunization groups. Such index takes into consideration both T_H1 IgG2a and IgG3 subclasses compared to T_H2 IgG1 subclass. The T_H1 : T_H2 index showed that, in sera of animals immunized with HIV-VLPs alone, the antibody response to p24 and gp140 was T_H2 polarized (T_H1 : T_H2 index 0.66 and 0.22, respectively). In contrast, in sera of mice immunized with adjuvanted HIV-VLPs, the antibody response to p24 was markedly skewed towards a T_H1 profile (T_H1 : T_H2 index > 1), and such effect was more pronounced when HIV-VLPs were

adjuvanted in poly(I:C) (T_H1 : T_H2 index 6) (Table 1). Also for gp140, the formulation of HIV-VLPs in poly(I:C) adjuvant induced a skewing towards a T_H1 profile (T_H1 : T_H2 index 2) (Table 1). IgG2b titers were excluded from the index calculation because the relationship between this IgG subclass and T_H -polarization is still debated [82,83].

Discussion

The pattern of IgG subclass has been shown to play a role in the course of HIV infection and it has been reported to vary with progression status. In particular, a strong T_H1 polarizing IgG subclasses as well as a broad IgG subtype response has been associated with long-term non-progressor status [28-30,84].

In order to determine the pattern of IgG subclasses induced by HIV-1 antigens packed in particulate structures as Virus Like Particles and to investigate the modulation of such pattern by T_H1 -inducing adjuvants, Balb/c mice were immunized intradermally with HIV-VLPs alone or formulated with CpG ODN1826 or poly(I:C) adjuvants.

Results shown in the present study confirmed the ability of HIV-VLPs to induce strong humoral immune response and both adjuvants were able to enhance the immunogenicity of HIV-VLPs, inducing a 3-9 fold increase in the total IgG titers for both p24 and gp140. The kinetic of induced humoral immune response showed a similar trend in sera from each immunization group, although the poly(I:C) induced a more sustained titer.

Evaluation of IgG subclasses demonstrated that HIV-VLPs alone induced anti-p24 and anti-gp140 IgG1 and IgG3 subclasses with no IgG2a elicitation. On the contrary, CpG ODN1826 and poly(I:C) showed the same capacity to enhance titers of anti-p24 and anti-gp140 IgG2a and IgG2b subclasses, compared to HIV-VLPs alone. In addition, only poly(I:C) was able to induce an enhancement also in IgG1 and IgG3 subclasses,

Table 1 T_H1 : T_H2 index for p24 and gp140

p24	VLP	VLP+ODN1826	VLP+poly(I:C)
IgG1 (T_H2)	300	300	900
IgG2a (T_H1)	100	900	8,100
IgG3 (T_H1)	300	300	2,700
T_H1 : T_H2 index	0.66	2	6
gp140	VLP	VLP+ODN1826	VLP+poly(I:C)
IgG1 (T_H2)	900	900	900
IgG2a (T_H1)	100	900	2,700
IgG3 (T_H1)	300	300	900
T_H1 : T_H2 index	0.22	0.66	2

The index has been calculated as described in Materials and Methods section. Index < 1 = T_H2 polarization. Index > 1 = T_H1 polarization.

resulting in the broadest IgG subclass pattern of immune response. Such results indicate that antibody profile induced by HIV-VLP in mice is T_H2 for both p24 and gp140 and that formulation in both adjuvants results in a T_H1 skewed IgG pattern. In particular, in our experimental model, poly(I:C) scores as the most potent in re-directing the T_H pattern, in agreement to previous observations [85,86].

Such finding is further confirmed by the $T_H1:T_H2$ index which evaluates the ratio between both T_H1 associated IgG subclasses (IgG2a and IgG3) and T_H2 associated (IgG1) subclass. Indeed, considering that an index value > 1 stands for a T_H1 polarization, the index in sera from animals immunized with poly(I:C)-adjuvanted HIV-VLPs scored the highest.

Our results confirm that HIV-VLPs represent an effective antigenic presentation and delivery system to prime the humoral immune response, eliciting mainly IgG1 subclass antibodies (T_H2 profile) with other subclasses represented at low titer (IgG2b and IgG3) or not present at all (IgG2a). We demonstrated that T_H1 -inducing adjuvants, and in particular the poly(I:C), were able to broaden the IgG subclasses response and to re-direct the immune response toward a T_H1 -biased pattern. In particular, HIV-VLPs formulated in poly(I:C) adjuvant elicited the highest titer of IgG3 subclass which has been claimed to mediate the HIV neutralization in sera from HIV-infected individuals [87,88]. However all the known broadly neutralizing antibody (i.e. IgGb12, VRCO1, 2G12, 2F5 and 4E10) belong to IgG1 antibody subclass with the exception of 447 that is an IgG3 antibody. Nevertheless, crystallographic analysis of such broadly neutralizing antibodies reveal molecular structures (i.e., longer complementary determining region (CDR) H3) which suggest that these IgG1 monoclonal antibodies show properties similar to the IgG3 subclass [89-91]. These studies indicate that molecular characteristics of the IgGs (i.e., flexibility of the antibody, mobility of the F(ab) or antigen binding site) are relevant for an efficient neutralizing activity of HIV.

In this perspective, studies focused on the formulation of vaccine candidates in adjuvants able not only to enhance immunogenicity but also to re-direct IgG subclass response, may represent a key aspect in the vaccinology field. In fact, adjuvant formulations can be tailored to enhance the required immune response (antibody, cell mediated, mucosal immunity) appropriate for individual causative infectious agents [92].

Acknowledgements

The study was supported by the European Community's Seventh Framework Programme NGIN (FP7/2007-2013) under grant agreement n° 201433. MT and MLV are funded by the NGIN Programme. Recombinant HIV p24 (NIBSC-

CFAR, Catalog #EVA620) was obtained through the NIBSC Centralised Facility for AIDS Reagents, Hertfordshire, UK. Homologous A clade trimeric gp140 was generously produced by G. Stuart-Jones, Oxford, UK, within the NGIN Consortium.

Authors' contributions

MLV performed the studies and contributed to writing the paper; MT contributed to HIV-VLPs preparation; MLT contributed to the data analysis; FMB supervised the whole project; LB was responsible for the overall planning and coordination of the study as well as writing the paper. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 10 June 2011 Accepted: 5 January 2012

Published: 5 January 2012

References

1. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L: Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. *Lancet Infect Dis* 2010, **10**:305-316.
2. Buonaguro L, Tornesello ML, Buonaguro FM: Virus-Like Particles as Particulate Vaccines. *Curr HIV Res* 2010, **8**:299-399.
3. Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P: Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. *Eur J Immunol* 1996, **26**:2595-2600.
4. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF: Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. *Eur J Immunol* 2002, **32**:818-825.
5. Buonaguro FM, Tornesello ML, Buonaguro L: Virus-like particle vaccines and adjuvants: the HPV paradigm. *Expert Rev Vaccines* 2009, **8**:1379-1398.
6. Andre FE, Safary A: Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. *Postgrad Med J* 1987, **63**(Suppl 2):169-177.
7. Harper DM: Currently approved prophylactic HPV vaccines. *Expert Rev Vaccines* 2009, **8**:1663-1679.
8. Harper DM: Preliminary HPV vaccine results for women older than 25 years. *Lancet* 2009, **373**:1921-1922.
9. Grgacic EV, Anderson DA: Virus-like particles: passport to immune recognition. *Methods* 2006, **40**:60-65.
10. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM: Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. *PLoS One* 2008, **3**:e1501.
11. Deml L, Speth C, Dierich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. *Mol Immunol* 2005, **42**:259-277.
12. Young KR, McBurney SP, Karkhanis LU, Ross TM: Virus-like particles: designing an effective AIDS vaccine. *Methods* 2006, **40**:98-117.
13. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM: Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. *J Virol* 2005, **79**:7059-7067.
14. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM: DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. *Vaccine* 2007, **25**:5968-5977.
15. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ: Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. *Proc Natl Acad Sci USA* 2003, **100**:6753-6758.
16. Hammarstrom L, Smith CI: IgG subclasses in bacterial infections. *Monogr Allergy* 1986, **19**:122-133.
17. Linde A, Sundqvist VA, Mathiesen T, Wahren B: IgG subclasses to subviral components. *Monogr Allergy* 1988, **23**:27-32.
18. Ferrante A, Beard LJ, Feldman RG: IgG subclass distribution of antibodies to bacterial and viral antigens. *Pediatr Infect Dis J* 1990, **9**:S16-S24.

19. Powers DC: Effect of age on serum immunoglobulin G subclass antibody responses to inactivated influenza virus vaccine. *J Med Virol* 1994, **43**:57-61.
20. Sanders LA, Rijkers GT, Tenbergen-Meekes AM, Voorhorst-Ogink MM, Zegers BJ: Immunoglobulin isotype-specific antibody responses to pneumococcal polysaccharide vaccine in patients with recurrent bacterial respiratory tract infections. *Pediatr Res* 1995, **37**:812-819.
21. Adderson EE, Shackelford PG, Quinn A, Carroll WL: Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. *J Immunol* 1991, **147**:1667-1674.
22. Adderson EE, Shackelford PG, Quinn A, Wilson PM, Cunningham MW, Insel RA, Carroll WL: Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. *J Clin Invest* 1993, **91**:2734-2743.
23. Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G: Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. *N Engl J Med* 1980, **303**:178-182.
24. Bachmann MF, Zinkernagel RM: The influence of virus structure on antibody responses and virus serotype formation. *Immunol Today* 1996, **17**:553-558.
25. Schumaker VN, Calcott MA, Spiegelberg HL, Muller-Eberhard HJ: Ultracentrifuge studies of the binding of IgG of different subclasses to the C1q subunit of the first component of complement. *Biochemistry* 1976, **15**:5175-5181.
26. Anderson CL, Loone RJ: Human leukocyte IgG Fc receptors. *Immunology Today* 1986, **7**(9):264-266, Ref Type: Journal (Full).
27. Snapper CM, Finkelman FD: Immunoglobulin class switching. In *Fundamental Immunology*. Edited by: Paul WE. Philadelphia: Lippincott-Raven; 1999:831.
28. Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP: IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. *AIDS Res Hum Retroviruses* 2010, **26**:445-458.
29. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynard M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C: HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. *AIDS Res Hum Retroviruses* 2001, **17**:1435-1446.
30. Sundqvist VA, Linde A, Kurth R, Werner A, Helm EB, Popovic M, Gallo RC, Wahren B: Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. *J Infect Dis* 1986, **153**:970-973.
31. Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB: MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. *AIDS Res Hum Retroviruses* 1999, **15**:921-930.
32. Jankovic D, Caspar P, Zweig M, Garcia-Moll M, Showalter SD, Vogel FR, Sher A: Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. *J Immunol* 1997, **159**:2409-2417.
33. Visciano ML, Tuen M, Gorny MK, Hioe CE: In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. *Virology* 2008, **372**:409-420.
34. Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP: Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. *Virology* 2009, **389**:108-121.
35. Chin'ombe N, Bourn WR, Williamson AL, Shephard EG: Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. *Virol J* 2009, **6**:87.
36. Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr: Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. *AIDS Res Hum Retroviruses* 2008, **24**:271-281.
37. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA: Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. *J Immunol* 2005, **174**:7676-7683.
38. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. *J Immunol* 1998, **160**:870-876.
39. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. *Nature* 2000, **408**:740-745.
40. Baker PJ, Hiernaux JR, Fauntleroy MB, Stashak PW, Prescott B, Cantrell JL, Rudbach JA: Ability of monophosphoryl lipid A to augment the antibody response of young mice. *Infect Immun* 1988, **56**:3064-3066.
41. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL: CpG ODN can redirect the Th bias of established Th2 immune responses in adult and young mice. *FEMS Immunol Med Microbiol* 2001, **32**:65-71.
42. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumppheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Muller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R: Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. *PLoS Pathog* 2009, **5**:e1000373.
43. Wuorimaa T, Dagan R, Vakevainen M, Bailleux F, Haikala R, Yaich M, Eskola J, Kayhty H: Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. *J Infect Dis* 2001, **184**:1211-1215.
44. Lefeber DJ, aissa-Trouw B, Vliegthart JF, Kamerling JP, Jansen WT, Kraaijeveld K, Snippe H: Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. *Infect Immun* 2003, **71**:6915-6920.
45. Buonaguro L, Del Gaudio E, Monaco M, Greco D, Corti P, Beth-Giraldo E, Buonaguro FM, Giraldo G: Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of HIV 1 isolates from Gulu-Northern Uganda. *J Virol* 1995, **69**:7971-7981.
46. Buonaguro L, Buonaguro FM, Russo F, Tornesello ML, Beth-Giraldo E, Wagner R, Wolf H, Giraldo G: A novel gp120 sequence from an HIV-1 isolate of the A clade identified in North Uganda. *AIDS Res Hum Retroviruses* 1998, **14**:1287-1289.
47. Buonaguro L, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, Wagner R, Michelson S, Prevost M-C, Wolf H, Giraldo G: High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. *Antiviral Research* 2001, **49**:35-47.
48. Tagliamonte M, Visciano ML, Tornesello ML, De SA, Buonaguro FM, Buonaguro L: HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. *Vaccine* 2011.
49. Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, Sempala SDK, Giraldo G, Buonaguro FM: Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). *Antiviral Research* 2002, **54**:189-201.
50. Visciano ML, Diomedea L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L: Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. *Vaccine* 2011.
51. Aricò E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM, Buonaguro L: Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. *J Transl Med* 2005, **3**:45.
52. Buonaguro L, Monaco A, Arico E, Wang E, Tornesello ML, Lewis GK, Marincola FM, Buonaguro FM: Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. *BMC Bioinformatics* 2008, **9**(Suppl 2):S5.
53. Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM: Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles. *J Virol* 2009, **83**:304-313.
54. Buonaguro L, Tornesello ML, Jewis GK, Buonaguro FM: Short communication: limited induction of IL-10 in PBMCs from HIV-infected

- subjects treated with HIV-VLPs. *AIDS Res Hum Retroviruses* 2009, **25**:819-822.
55. Klinman DM, Currie D, Gursel I, Verthelyi D: **Use of CpG oligodeoxynucleotides as immune adjuvants.** *Immunol Rev* 2004, **199**:201-216.
56. Klinman DM: **Adjuvant activity of CpG oligodeoxynucleotides.** *Int Rev Immunol* 2006, **25**:135-154.
57. Jin B, Sun T, Yu XH, Liu CQ, Yang YX, Lu P, Fu SF, Qiu HB, Yeo AE: **Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.** *J Biomed Biotechnol* 2010, **2010**:690438.
58. Meylan E, Tschopp J: **Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses.** *Mol Cell* 2006, **22**:561-569.
59. Matsumoto M, Seya T: **TLR3: interferon induction by double-stranded RNA including poly(I:C).** *Adv Drug Deliv Rev* 2008, **60**:805-812.
60. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM: **Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly I:C as adjuvant.** *J Exp Med* 2009, **206**:1589-1602.
61. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF: **Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.** *J Immunol* 2006, **176**:2074-2078.
62. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA: **Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates.** *Vaccine* 2010, **28**:7256-7266.
63. Le BA, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF: **Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.** *Nat Immunol* 2003, **4**:1009-1015.
64. Le BA, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF: **Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.** *J Immunol* 2006, **176**:4682-4689.
65. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: **CpG motifs in bacterial DNA trigger direct B-cell activation.** *Nature* 1995, **374**:546-549.
66. Verthelyi D, Zeuner RA: **Differential signaling by CpG DNA in DCs and B cells: not just TLR9.** *Trends Immunol* 2003, **24**:519-522.
67. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: **CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.** *Proc Natl Acad Sci USA* 1996, **93**:2879-2883.
68. Sun S, Zhang X, Tough DF, Sprent J: **Type I interferon-mediated stimulation of T cells by CpG DNA.** *J Exp Med* 1998, **188**:2335-2342.
69. Stacey KJ, Sweet MJ, Hume DA: **Macrophages ingest and are activated by bacterial DNA.** *J Immunol* 1996, **157**:2116-2122.
70. Ballas ZK, Rasmussen WL, Krieg AM: **Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.** *J Immunol* 1996, **157**:1840-1845.
71. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: **Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.** *Nat Med* 1997, **3**:849-854.
72. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: **CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.** *Proc Natl Acad Sci USA* 1996, **93**:2879-2883.
73. Ballas ZK, Rasmussen WL, Krieg AM: **Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.** *J Immunol* 1996, **157**:1840-1845.
74. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: **Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.** *Nat Med* 1997, **3**:849-854.
75. Halpern MD, Kurlander RJ, Pisetsky DS: **Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha.** *Cell Immunol* 1996, **167**:72-78.
76. Gupta RK, Siber GR: **Adjuvants for human vaccines—current status, problems and future prospects.** *Vaccine* 1995, **13**:1263-1276.
77. Krieg AM: **Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.** *Biochim Biophys Acta* 1999, **1489**:107-116.
78. McCluskie MJ, Davis HL: **CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.** *J Immunol* 1998, **161**:4463-4466.
79. Visciano ML, Diomedede L, Tagliamonte M, Tornesello ML, Asti V, Bonsel M, Buonaguro FM, Lopalco L, Buonaguro L: **Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.** *Vaccine* 2011.
80. Rovinski B, Haynes JR, Cao SX, James O, Sia C, Zolla-Pazner S, Matthews TJ, Klein MH: **Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.** *J Virol* 1992, **66**:4003-4012.
81. Tagliamonte M, Visciano ML, Tornesello ML, De SA, Buonaguro FM, Buonaguro L: **HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line.** *Vaccine* 2011, **29**:4913-4922.
82. McIntyre TM, Klinman DR, Rothman P, Lugo M, Dasch JR, Mond JJ, Snapper CM: **Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells.** *J Exp Med* 1993, **177**:1031-1037.
83. Weiner HL: **Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.** *Microbes Infect* 2001, **3**:947-954.
84. Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debre P, Rouzioux C, Autran B: **Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.** *J Infect Dis* 2005, **191**:2053-2063.
85. Le BA, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF: **Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.** *Immunity* 2001, **14**:461-470.
86. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM: **Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response.** *J Exp Med* 2010, **207**:1485-1500.
87. Scharf O, Golding H, King LR, Eller N, Frazier D, Golding B, Scott DE: **Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.** *J Virol* 2001, **75**:6558-6565.
88. Gray ES, Madiga MC, Moore PL, Mlisana K, bdoool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L: **Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.** *J Virol* 2009, **83**:11265-11274.
89. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA: **Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.** *Proc Natl Acad Sci USA* 2010, **107**:11483-11488.
90. Saphire EO, Parren PW, Barbas CF, Burton DR, Wilson IA: **Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1.** *Acta Crystallogr D Biol Crystallogr* 2001, **57**:168-171.
91. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Kattinger H, Burton DR, Wilson IA: **Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.** *Science* 2003, **300**:2065-2071.
92. Vogel FR: **Improving vaccine performance with adjuvants.** *Clin Infect Dis* 2000, **30**(Suppl 3):S266-S270.

doi:10.1186/1479-5876-10-4

Cite this article as: Visciano et al.: Effects of adjuvants on IgG subclasses elicited by virus-like Particles. *Journal of Translational Medicine* 2012 **10**:4.